Quantification of Bacterial Load in Mouse Spleen and Liver After Systemic Infection
0 次观看 • 3:52 分钟 • July 1st, 2026
Loading...
Overview
This article demonstrates a protocol for quantifying bacterial load in spleen and liver tissues from mice experimentally infected with an intracellular bacterial pathogen, such as Listeria monocytogenes. The method involves tissue collection, mechanical and detergent-based lysis, serial dilution, plating on nutrient agar, and colony counting to assess bacterial burden in each organ.
Key Study Components
Area of Science
- Microbiology
- Immunology
- Infectious Disease Research
Background
- Spleen and liver act as immune filters, accumulating bacteria during systemic infection.
- Quantifying bacterial load in these organs is essential for studying host-pathogen interactions and immune responses.
- Intracellular pathogens like Listeria monocytogenes are commonly used to model infection and immune response.
- Accurate measurement of bacterial burden informs on infection progression and host defense mechanisms.
Purpose of Study
- To provide a reproducible protocol for measuring bacterial load in mouse spleen and liver post-infection.
- To facilitate studies of host immune responses, particularly interferon-γ responses, during intracellular bacterial infection.
- To enable assessment of infection severity and tissue-specific bacterial accumulation.
Methods Used
- Dissection and collection of spleen and liver tissues from infected mice.
- Mechanical disruption using glass beads and a bead mill homogenizer in the presence of a non-ionic detergent lysis buffer.
- Serial dilution of tissue homogenates in 0.1% Triton X-100 in PBS.
- Plating of diluted homogenates on BHI agar and overnight incubation at 37°C.
- Colony counting on plates with up to 300 colonies to determine bacterial load.
Main Results
- Efficient release of viable bacteria from tissue-resident phagocytes using mechanical and detergent-based lysis.
- Accurate quantification of bacterial burden in spleen and liver by colony counting.
- Reproducible measurement of peak infection bacterial load, typically assessed on day three post-infection.
- Protocol enables comparison of bacterial loads across experimental groups or time points.
Conclusions
- This protocol provides a reliable method for quantifying bacterial load in mouse tissues following infection with intracellular pathogens.
- It supports studies investigating host immune responses and infection dynamics.
- The approach is adaptable for various bacterial pathogens and experimental designs.
Frequently Asked Questions
What is the main purpose of this protocol?
The protocol is designed to quantify bacterial load in spleen and liver tissues from mice infected with intracellular pathogens, enabling studies of host immune responses and infection dynamics.
How are bacteria released from tissue samples?
Bacteria are released by mechanically disrupting tissues with glass beads in a lysis buffer containing a non-ionic detergent, which permeabilizes host cells while preserving bacterial viability.
Why are serial dilutions performed before plating?
Serial dilutions ensure that plated samples yield countable numbers of colonies, allowing for accurate quantification of bacterial burden in each tissue.
What type of agar is used for plating the bacteria?
BHI (Brain Heart Infusion) agar is used as a nutrient-rich medium to support the growth of bacteria released from tissue homogenates.
How is the peak infection time point determined?
Peak infection is typically assessed on day three post-infection, when bacterial loads in tissues are expected to be highest.
Can this protocol be adapted for other bacterial pathogens?
Yes, the protocol can be adapted for other intracellular bacterial pathogens by adjusting incubation conditions and media as needed.
What safety precautions should be taken during tissue dissection?
All dissections should be performed using sterile instruments and proper disinfection procedures to prevent contamination and ensure biosafety.
Executive Industry Relevance
Quantitative measurement of bacterial load in mouse spleen and liver provides a robust readout for evaluating host-pathogen interactions and immune response efficacy in preclinical infectious disease models. This approach enables mechanistic de-risking and supports predictive confidence in target validation for anti-infective drug discovery. Accurate organ-specific bacterial quantification informs portfolio decisions at key discovery and lead identification inflection points.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables rigorous testing of therapeutic hypotheses targeting host or pathogen pathways.
- Supports biological de-risking by quantifying infection burden in relevant immune organs.
- Facilitates functional validation of immune-modulating targets through quantitative bacterial readouts.
- Provides data for predictive confidence in advancing anti-infective candidates.
Screening & Assay Development
- Establishes validated, reproducible workflows for measuring bacterial burden in tissue samples.
- Delivers quantitative outputs suitable for assay standardization and cross-study comparison.
- Supports scalability for screening compound efficacy in vivo.
- Enables reliable evaluation of intervention impact on infection progression.
Translational & Preclinical Research
- Aligns with disease-relevant models for translational biomarker development.
- Ensures continuity from early discovery through preclinical validation of anti-infective strategies.
- Provides risk-adjusted data for advancement decisions in infectious disease portfolios.
- Supports mechanistic de-risking by linking bacterial load to immune response outcomes.
Pipeline & Workflow Integration
This quantification method integrates into the discovery-to-preclinical continuum, supporting both target validation and lead identification in infectious disease research.
- Discovery Biology: Enables hypothesis testing and pathway clarification by measuring infection burden in immune organs.
- Screening: Provides reproducible, quantitative outputs for evaluating compound efficacy in vivo.
- Analytics: Delivers colony count data for statistical comparison of experimental groups and conditions.
- Translational Research: Bridges discovery findings to preclinical validation using disease-relevant infection models.
- Enterprise Reuse: Offers a standardized, adaptable protocol for diverse intracellular bacterial pathogens.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in infection models.
- Operational Value: Promotes standardization, reproducibility, and scalability across studies.
- Strategic Value: Informs go/no-go decisions and enhances capital efficiency in anti-infective R&D.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of infectious disease candidates.
Implementation Considerations
- Requires expertise in animal handling, tissue dissection, and microbiological techniques.
- Needs access to bead mill homogenizers, sterile instruments, and BHI agar plates.
- Demands cross-team standardization of tissue processing and colony counting protocols.
- Adaptable to various mouse models and intracellular bacterial pathogens with protocol adjustments.
- Dependent on maintaining sterility and biosafety throughout tissue collection and processing.
Biopharma FAQs
Why does null hypothesis testing matter for colony count comparisons?
Null hypothesis testing enables objective assessment of whether observed differences in bacterial load between experimental groups are statistically significant, supporting robust target validation and mechanistic de-risking in infectious disease models.
How does independent variable isolation improve tissue homogenate analysis?
Isolating variables such as infection time point, tissue type, and homogenization conditions ensures that changes in bacterial load reflect true biological effects, enhancing the reliability of discovery-stage findings.
What do quantitative colony counts enable in infection studies?
Quantitative colony counts provide precise measurement of bacterial burden, enabling comparison of intervention efficacy, dose response, and immune modulation across experimental arms in preclinical research.
Why are replication requirements critical for cross-functional data use?
Replication ensures that bacterial load measurements are reproducible and reliable, facilitating data sharing and interpretation across discovery, screening, and translational research teams.
Which statistical analysis capabilities are needed before colony count implementation?
Teams must be equipped to perform statistical analyses such as t-tests or ANOVA on colony count data to validate significance, support decision-making, and ensure data integrity in R&D workflows.
06:50
用小鼠脾评估病原体相关分子模式对时钟基因表达的影响
相关视频
0 观看次数
08:38
细菌病原体在细胞和有机水平宿主反应探针中的应用
相关视频
0 观看次数
09:11
李斯特菌单细胞基因感染后小鼠脾脏原位干扰素伽马生产的成像
相关视频
0 观看次数
12:50
测量细菌感染小鼠和免疫反应李斯特菌
相关视频
0 观看次数
13:22
γHV68感染小鼠的测量
相关视频
0 观看次数
02:42
慢性肠道感染小鼠模型中组织细菌负荷的定量化
相关视频
0 观看次数
04:21
李斯特菌单核细胞增生体尾静脉注射后，量化小鼠心脏中的细菌负荷
相关视频
0 观看次数
02:03
评估小鼠脾脏中的细菌负荷以进行感染研究
相关视频
0 观看次数
07:43
在小鼠实验为细菌性肺炎的诱导和表型非侵入性和技术上非密集型方法
相关视频
0 观看次数
10:10
实验性感染李斯特菌作为研究主机干扰素γ响应模型
相关视频
0 观看次数
最后更新：1 八月 2026